PCV interchangeability: Summarizing available evidence to inform policy recommendations

This dossier summarizes the available evidence on pneumococcal conjugate vaccine (PCV) interchangeability to support countries as they consider adding or switching the products used in their national immunization programs. We reviewed current evidence to assess the biologic and epidemiologic impact described in settings where children received two different PCV products. This resource aims to:

  1. Review available evidence on PCV interchangeability from an individual beneficiary level, synthesizing data on children who complete their PCV schedule with mixed products
  2. Provide synthesized evidence to inform policies on PCV procurement, specifically feasibility of brand switching

View the PCV Interchangeability Evidence Dossier (updated November 2019)